Quality of sleep in chronic migraine patients treated with fremanezumab - 6 months follow-up.

UNLABELLED: ОBJECTIVE: Sleep disturbances are frequent in patients with chronic migraine (CM). Monoclonal antibodies, such as fremanezumab, may offer better-tolerated and efficacious alternatives to traditional migraine pharmacological preventive therapies. The aim was to assess the quality of sleep (QoS) in patients with CM, during the follow-up period of 6 months, during which they were treated with fremanezumab once per month.

METHODS

The study included 82 patients with CM and 80 healthy control subjects. The study included the application of the Pittsburgh Sleep Quality Index (PSQI), Hamilton scales for the assessment of anxiety (HAM-A) and depression (HAM-D), and the 6-item Headache Impact Test (HIT-6).

RESULTS

The PSQI global score and all subscores in patients with CM were significantly higher than in the control group (p < 0.01). We noticed a statistically significant difference between the results in the PSQI global score between the first and third testing points (p < 0.01). Also, some subscores were statistically significantly better during the follow-up period. Patients with higher scores on HIT-6, HAM-A, and HAM-D had higher scores on PSQI. Higher scores on PSQI were also noticed in female patients, the elderly, and patients with higher body mass index (BMI) levels.

CONCLUSION

The prevalence of sleep disturbance in CM patients is relatively high before starting the effective prophylactic treatment. Fremanezumab therapy had a significant beneficial influence on the QoS of CM patients. High levels of sleep disturbance correlate with higher disease-related disability, anxiety, depression, and some characteristics of the disease.